Glasgow, Scotland (PRWEB) September 26, 2015
HCi Viocare (OTCQB: VICA), (the "Company") today announced that their cutting edge health tech research centre, set up in Glasgow to develop and commercialize smart sensors that help prevent diabetic foot ulcers and athletic injuries, is being officially opened today by First Minister and local MSP Nicola Sturgeon.
The Company’s new research and development centre was opened together with its first prosthetics and orthotics clinic. The Company has already brought substantial inward investment into the city’s Govan area, having so far created five scientific and professional jobs at its dual facility, with more to come.
Nicola Sturgeon said “I’m delighted to open this new facility and very much welcome HCi Viocare’s investment in Govan. I congratulate everyone involved in establishing the centre and look forward to seeing how this innovative technology progresses.”
HCi Viocare’s co-founder and Chief Technology Officer Christos Kapatos commented, “Today’s opening is an important landmark for HCi Viocare. As well as actively seeking partners to commercialise our smart sensors and other technologies internationally, we aim to extend prosthetics and orthotics clinics across Mediterranean Europe based on the model being established by our new Glasgow clinic.”
The Company’s near-market innovations include patent-pending low cost, smart sensing systems, incorporated into insoles for monitoring and preventing diabetic foot ulcers, as well as for monitoring athletic performance and preventing common running injuries. Multiple adaptations of the technology exist in health and sports sectors, including smart mattresses for preventing pressure sores.
HCi Viocare’s prosthetics and orthotics clinic is the only independent provider in Scotland. As well as seeing clients from Scotland, the north of England and beyond, it will act as a centre of reference and training for the company’s future clinics in European and Middle Eastern countries, where prosthetics and orthotics services are generally less developed than in the UK.
Dr Kapatos added, “Scotland is renowned for its innovation, highly skilled workforce and commitment to commercialisation. We value having our technology hub and first clinic here in Glasgow. We expect to create further high calibre jobs, recruiting from my alma mater the University of Strathclyde where possible, contributing to our company’s success as well as to Scotland’s economy and international reputation.”
About HCi Viocare
HCi Viocare has a dual, complementary business model of 1) creating the first cross-border independent chain of prosthetics and orthotics (P&O) and diabetic foot clinics in Europe and the Middle East, and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health and wellbeing areas, for licensing to established industry participants. HCi Viocare is listed on the OTC Markets in the USA (OTCQB: VICA), has its executive office in Athens, Greece, and R&D centre in Glasgow.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to: the engagement of partners to commercialise our smart sensors and other technologies internationally, or the extension of prosthetics and orthotics clinics across Mediterranean Europe based on the model being established by our new Glasgow clinic, or the ability of the clininc to act as a centre of reference and training for the company’s future clinics in European and Middle Eastern countries. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, nor that it will be successful in receiving an award or grant for any of its new technology concepts. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
For further information about HCi Viocare please visit the Company's website at http://www.hciviocare.com